Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare launches new global registry of VTE patients

Bayer HealthCare launches new global registry of VTE patients

5th September 2013

Bayer HealthCare has announced the launch of a new independent global academic registry of symptomatic venous thromboembolism (VTE) patients.

Entitled Garfield VTE, the registry will include data from more than 10,000 patients and has been launched in partnership with the Thrombosis Research Institute at the 2013 European Society of Cardiology Congress.

It will study the acute and long-term management of patients suffering from venous blood clots with both traditional dual-drug approaches and novel anticoagulants such as Bayer HealthCare's single-drug solution Xarelto.

The company is supporting the registry with an unrestricted educational grant, with the aim of helping payors, policymakers and prescribers to improve safety, outcomes and utilisation of healthcare resources.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said registries of this kind "will provide important insights about the real-world use of Xarelto and will help tailor our responsible use programme for Xarelto to the needs of patients and physicians".

Xarelto was recommended as a treatment for pulmonary embolisms and recurrent deep vein thrombosis by the UK's National Institute for Health and Care Excellence earlier this year.ADNFCR-8000103-ID-801633913-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.